19 December 2019
14 January 2020


Fedegari Group is banking on new technology to grow its operations in the regional pharmaceutical sector.

The pharmaceutical industry has been growing worldwide at a steady pace and it is one of the sectors that heavily invests significantly in state-of-the-art technologies.
The growth of Fedegari Group has followed the trend of the industry. One of the secrets to its success is that the company has always invested in the engineering of sterile plants with the highest performances possible.
The company recently expanded its main manufacturing facilities in Italy with approximately six MEUR investments in state-of-the-art machinery to support an industrial strategy with a 4.0 approach. This includes automated warehouses, laser- and waterjet-cutting machines. a new punch press and other machinery.

autoclave ad acqua surriscaldata


Following the incorporation of Fedegari Asia Pte Ltd in Singapore in 2008, the company has expanded to two offices with 26 employees in 11 years. The company plans to increase its headcount to 30 in 2020.
Managing director of Fedegari Asia, Mr Luca lnnacolo, says: “We chose Singapore because it is the perfect hub to do business in Asia for its infrastructure, legal framework, vibrant financial centre and skilled work-force.” Mr lnnacolo adds that operating in Singapore has helped the company to understand the Asian culture better before it moved into other regional countries.
Fedegari Asia is also in charge of the operations of the Group’s subsidiary in Shanghai, China and the technical support centre in Hyderabad, India.
Its direct presence in such countries is essential. In terms of quantity, China and India are the biggest producers of drugs in the world. The Asia-Pacific entities generate more than 30 per cent of the total turnover of the Group and will lead the ambitious market expansion plan of the Fedegari family.

Process Controller Thema4

Headquarters in Albuzzano, Italy.


The use of new technologies has helped the company to better utilise plants and processes that are becoming increasingly complex. For example, the use of Artificial Intelligence, smart sensors and cloud computing operators can now monitor how clients are using Fedegari machines. In this way they can schedule their maintenance if necessary, which minimises machine downtime. Technology in this case is for the benefit of the end user to improve the performance of the machines.
Fedegari Asia hopes to leverage on Singapore’s focus on advanced technology to grow its business. Mr lnnacolo says: “We are following with keen interest the investments that are being made in Singapore with regards to its well-developed IT infrastructure. We would like to be part of the process as providers and as users by cooperating with universities, government bodies and private companies as we are doing in Italy.”
Fedegari Group was founded in the early 1950s in Albuzzano, Italy. Today, it is a leader in the design and manufacturing of advanced sterilisation systems for pharmaceutical production, including custom moist and dry heat sterilisers, washers, chemical bio-decontamination units, contamination control solutions and integrated systems with robotised handling. Fedegari systems often exceed the highest global standards in pharmaceutical manufacturing, and are used by many of the largest biopharmaceutical companies in the world. Its systems and equipment operate in more than 100 countries.
The Group is strongly product and process oriented. Its customer-centric approach has led them to build very close relationships with the biggest pharmaceutical companies in the world.